Objective Costs associated with HPV-related diseases such as cervical dysplasia, cervical
cancer, and genital warts have not been evaluated in Sweden. These costs must be …

To assess the epidemiological and economic impact of alternative quadrivalent human
papillomavirus (HPV) vaccine strategies in Norway, we adapted a previously published …

The aim of this study was to evaluate the total burden and health care provider costs of
prevention, management and treatment of HP‐related genital disease outcomes including …

Objective: A transmission dynamic model was used to assess the epidemiological and
economic impact of a quadrivalent human papillomavirus (HPV)(6/11/16/18) vaccine in …

Introduction The UK implemented a single-dose HPV vaccination policy in September 2023,
aiming for sustained protection, better vaccine coverage, and reduced healthcare costs. This …

Aim The objective of this study was to estimate and compare the cost-effectiveness of
switching from a bivalent to a nonavalent human papillomavirus (HPV) vaccination program …

Objective: Based on positive safety and efficacy data, a quadrivalent Human PapillomaVirus
(HPV) vaccine has been approved in Switzerland to prevent HPV types 6, 11, 16 and 18 …

Background High-risk (HR) human papillomavirus (HPV) infection is an established cause of
malignant disease. We used a societal perspective to estimate the cost of HR HPV-related …

Background: The United Kingdom (UK) switched from using the 4-valent human
papillomavirus (HPV) vaccine (Gardasil®) to the 9-valent vaccine (Gardasil 9®) in 2021 …

Background Sweden revised their cervical cancer screening program in 2017 to include
cytology-based screening for women aged 23–29 years and primary human papillomavirus …